☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
mirum pharmaceuticals
Mirum Pharmaceuticals Receives the US FDA Approval for Ctexli to Treat Cerebrotendinous Xanthomatosis
February 24, 2025
Mirum Pharmaceuticals’ Livmarli Receives the EC’s Approval to Treat Progressive Familial Intrahepatic Cholestasis (PFIC)
July 9, 2024
Mirum Pharmaceuticals’ Livmarli (maralixibat) Receives the CHMP’s Positive Opinion for Progressive Familial Intrahepatic Cholestas...
May 31, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.
